Lyme Disease Testing Market – By Diagnostic Technology, By Sample Type, By Patient Type, By End Use – Global Forecast, 2025 to 2034

Lyme Disease Testing Market Size

The global lyme disease testing market size was valued at USD 6.7 billion in 2024 and is expected to exhibit growth at a CAGR of 5.7% from 2025 to 2034. The market is driven by several factors that collectively enhance its growth potential. First, the increasing prevalence of Lyme disease, particularly in endemic regions like North America and parts of Europe, significantly boosts the demand for diagnostic tests.
 

The Centers for Disease Control and Prevention (CDC) 2024, estimates that approximately 476,000 Lyme disease cases are diagnosed annually in the U.S., underscoring the need for robust diagnostic solutions?. Technological advancements in diagnostic methods are another critical driver. The development of highly sensitive and specific technologies, such as molecular diagnostics (e.g., PCR) and next-generation serological assays (e.g., ELISA), enables early and accurate detection, even in asymptomatic patients.
 

Moreover, point-of-care (POC) tests and at-home testing kits are gaining traction, offering convenient and rapid diagnostic options?. Rising awareness about the long-term complications of untreated Lyme disease, such as chronic neurological and musculoskeletal issues, is prompting early testing and treatment. Public health campaigns by governments and non-profit organizations have significantly contributed to this awareness?. Regulatory support and funding for research into tick-borne diseases are also spurring market growth.
 

Lyme disease testing involves diagnostic procedures to detect Borrelia burgdorferi, the bacteria responsible for Lyme disease, primarily transmitted through tick bites. Testing methods include serological tests like ELISA and Western blot, molecular diagnostics like PCR, and antigen-based tests. These tests analyze samples such as blood, cerebrospinal fluid (CSF), or urine to identify infection stages, enabling timely and accurate treatment. Early detection is vital to prevent severe complications.
 

Lyme Disease Testing Market Trends

The increasing prevalence of Lyme disease is a significant driver of the market. Lyme disease, caused by the spirochete bacterium Borrelia burgdorferi and transmitted through tick bites, has shown a marked rise in incidence globally, particularly in endemic regions like North America and Europe.
 

• The Centers for Disease Control and Prevention (CDC) reports that approximately 476,000 people are diagnosed and treated for Lyme disease annually in the U.S. alone, highlighting its widespread nature. This surge in cases is attributed to factors such as climate change, which extends tick activity periods, and the expansion of deer and rodent populations that host these vectors.
   
• This increasing disease burden amplifies the need for early and accurate diagnostic tests to identify infections and guide timely treatments, especially given Lyme disease's potential to progress into chronic stages affecting neurological, cardiovascular, and musculoskeletal systems if left untreated. Regions with a high prevalence of Lyme disease are seeing significant investments in improving diagnostic infrastructure, further fueling the demand for reliable testing solutions.
   
• Moreover, rising public awareness of Lyme disease and its complications has led to increased testing, even for asymptomatic or mildly symptomatic individuals exposed to tick-prone areas. Diagnostic advancements, including highly sensitive serological tests like ELISA and Western blot, as well as molecular technologies such as polymerase chain reaction (PCR), cater to this growing demand. Public health initiatives, coupled with healthcare providers emphasis on preventive diagnostics, are also pivotal in driving the market forward.
   
• As Lyme disease prevalence continues to rise, the testing market is expected to expand, driven by advancements in technology and a focus on early-stage detection to mitigate long-term health impacts.
   

Lyme Disease Testing Market Analysis

Based on diagnostic technology, the market is segmented into serological test, nucleic acid test, urine antigen testing, lymphocytic transformation test, and immunofluorescent staining. The serological test segment is expected to expand at a CAGR of 6.2%, reaching over USD 5 billion by 2034.
 

• The segment is expected to witness significant growth in the market due to its established reliability, widespread adoption, and technological advancements. These tests, which include enzyme-linked immunosorbent assay (ELISA) and Western blot, are the most commonly used diagnostic methods for detecting Borrelia burgdorferi antibodies. Their accuracy in identifying Lyme disease at different stages, particularly during the later phase of infection, is a key driver.
   
• The growing prevalence of Lyme disease globally, especially in endemic regions like North America and parts of Europe, has significantly increased the demand for serological tests. Healthcare providers and public health initiatives focus on early detection to mitigate severe complications, further boosting the adoption of these tests. Additionally, advancements in serological testing technology have enhanced sensitivity and specificity, reducing false positives and negatives, which were common challenges in earlier versions.
   
• Regulatory endorsements, such as the Centers for Disease Control and Prevention's (CDC) two-tiered testing approach recommending ELISA followed by Western blot, also support the segment's dominance. The increasing availability of automated platforms and point-of-care (POC) devices for serological testing improves accessibility, particularly in remote or underserved regions.
   
• Moreover, rising awareness campaigns by governments and non-profit organizations educate at-risk populations about the importance of Lyme disease testing, encouraging broader utilization of serological tests. Combined with the expanding healthcare infrastructure and growing emphasis on preventive diagnostics, these drivers are poised to propel the serological test segment's growth over the forecast period.
   

Based on sample type, the lyme disease testing market is classified into blood, urine, CSF, and other blood samples. The blood segment held 52.2% share of the market in 2024, driven by several key factors.
 

• The segment is expected to hold a significant share, driven by several key factors. Blood samples are considered the gold standard in Lyme disease diagnostics due to their ability to detect antibodies and bacterial DNA effectively. Serological tests, such as ELISA (Enzyme-Linked Immunosorbent Assay) and Western blot, are commonly used to analyze blood samples, providing high sensitivity and specificity in identifying Lyme disease antibodies. These blood and blood components based tests offer a non-invasive, relatively simple method for diagnosis, making them widely used across healthcare settings.
   
• The convenience and accessibility of blood sample collection also contribute to the dominance of this segment. Blood can be easily drawn in clinical settings, making it more feasible for large-scale testing, particularly in endemic areas. Furthermore, advancements in blood-based molecular diagnostics, such as PCR (Polymerase Chain Reaction) testing, have improved the accuracy of detection by amplifying bacterial DNA, even during early stages of the disease.
   
• As awareness of Lyme disease increases and early diagnosis becomes critical in preventing long-term complications, the demand for blood tests will likely continue to grow. Additionally, the establishment of robust diagnostic infrastructure, especially in regions with high infection rates, supports the ongoing expansion of the blood sample segment in the market.
   

Based on patient type, the lyme disease testing market is patient type into adult and pediatric. The adult segment was valued at USD 4.9 billion in 2024 and is expected to grow at a 6% CAGR between 2025 and 2034.
 

• The adult segment of the market is driven by several key factors that support its robust growth. First, increased exposure to tick-prone environments due to outdoor activities, travel, and work in endemic areas, such as forests and grasslands, significantly contributes to the rising incidence of Lyme disease among adults. This segment also benefits from growing public awareness of Lyme disease symptoms and the importance of early detection, as adults are more likely to seek medical help when experiencing symptoms such as fever, fatigue, and joint pain. Furthermore, advancements in diagnostic technologies like polymerase chain reaction (PCR) and serological tests, including ELISA and Western blot, have made testing more accessible and accurate, encouraging more individuals to undergo testing.
   
• Additionally, the increasing prevalence of comorbidities in adults, such as diabetes or cardiovascular disease, which can complicate the diagnosis and treatment of Lyme disease, further emphasizes the need for early and precise testing. Moreover, the rising awareness among healthcare providers about the importance of testing at-risk adult populations, especially those with chronic symptoms that could be linked to Lyme disease, is fueling the demand for diagnostic solutions. As outdoor activities and human-animal interactions increase, the adult segment is expected to continue expanding rapidly.

Based on end use, the lyme disease testing market is segmented into hospitals, diagnostic laboratories, and other end users. The hospitals segment dominated the market in 2024 and is anticipated to reach USD 5.3 billion by 2034.
 

• The hospitals segment is expected to continue dominating due to several key drivers. First, hospital-based diagnostics provide comprehensive testing options, ranging from blood tests to advanced molecular diagnostics, which are crucial for accurate and timely detection of Lyme disease. Hospitals are equipped with state-of-the-art technologies and skilled healthcare professionals capable of interpreting complex results, making them the preferred setting for diagnosing patients with Lyme disease.
   
• Additionally, increased patient visits to hospitals due to tick-borne diseases contribute to the demand for Lyme disease testing. Hospitals also serve as central hubs for disease management and treatment, offering a one-stop solution for both testing and therapeutic interventions. The growing number of chronic Lyme disease cases, which require ongoing medical attention, further fuels this trend, as hospitals provide specialized care for long-term symptoms.
   
• Hospitals benefit from regulatory support and government funding, particularly in endemic regions, to enhance diagnostic capabilities and tackle the growing prevalence of Lyme disease. This includes financial aid for purchasing advanced diagnostic instruments, which drives the market growth. Furthermore, hospitals are increasingly focusing on point-of-care (POC) testing, reducing the time for test results and enhancing treatment efficacy, thus improving patient outcomes.
   

U.S. Lyme disease testing market was valued at USD 2.6 billion in 2024 and is projected to grow substantially in the coming years.
 

• In the U.S., the market is primarily driven by the significant annual incidence of Lyme disease. The expansion of Lyme disease into new regions across the U.S. due to changing climate patterns and increased tick activity also contributes to rising testing demand. The U.S. benefits from an advanced healthcare system, which includes access to high-quality diagnostic tools such as PCR, ELISA, and Western blot tests, enabling early detection and treatment.
   
• Moreover, increased public awareness through campaigns by the CDC and other health organizations has made both individuals and healthcare professionals more proactive in seeking testing, especially in endemic areas. Government funding and research initiatives aimed at improving Lyme disease surveillance, prevention, and diagnosis further support the market’s growth.
   
• The availability of point-of-care testing (POC) is becoming increasingly popular, as it allows for faster diagnoses, improving treatment timelines and patient outcomes. With the ongoing spread of Lyme disease and continued efforts to improve detection and treatment options, the U.S. is poised for sustained growth in Lyme disease testing demand.
   

U.K. lyme disease testing market is projected to grow remarkably in the coming years.
 

• In the U.K., Lyme disease cases have been increasing, particularly in rural and woodland areas, where tick exposure is more common. This rise in cases has heightened awareness about the disease, both among healthcare providers and the general public, driving demand for accurate and efficient diagnostic tests. The National Health Service (NHS) recommends serological tests, such as ELISA and Western blot, for diagnosing Lyme disease, and the growing adoption of these tests in healthcare settings is boosting the market.
   
• The increasing popularity of outdoor activities, such as hiking and cycling, in tick-prone regions has led to more individuals seeking Lyme disease testing after potential tick bites, further fueling market growth. Furthermore, government health initiatives, including awareness campaigns and policies focusing on tick-borne diseases, have contributed to greater public knowledge of Lyme disease and its symptoms. This has encouraged more people to seek medical testing.
   
• In addition, the rise of telemedicine in the U.K. has further driven the market by facilitating remote consultations and follow-up care. Through telehealth platforms, patients can discuss their symptoms with healthcare professionals, receive guidance on testing, and access prescriptions for diagnostic tests, enhancing access to Lyme disease diagnostics, especially in rural or underserved areas. This integration of digital health solutions has become an important catalyst for market expansion.
   

China holds a dominant position in the Asia Pacific lyme disease testing market.
 

• In China, the market is gradually expanding due to increased awareness of tick-borne diseases and Lyme disease, particularly in rural and forested regions where ticks are more prevalent. As Lyme disease is less recognized compared to other diseases in China, awareness campaigns by health authorities and healthcare providers are essential for educating the public and physicians, leading to a growing demand for Lyme disease testing.
   
• Additionally, the increase in outdoor activities such as hiking, camping, and farming in tick-endemic areas has contributed to a higher risk of tick exposure, driving the need for diagnostic testing. The rapid growth of healthcare infrastructure, especially in rural areas, has improved access to Lyme disease diagnostic tests, which include both serological tests like ELISA and molecular diagnostics like PCR.
   
• Moreover, advances in diagnostic technologies and government initiatives aimed at controlling tick-borne diseases are encouraging more widespread testing. However, Lyme disease testing in China faces challenges, including limited physician knowledge and potential delays in diagnosis. Despite these barriers, the market is expected to see continued growth as awareness, healthcare access, and diagnostic capabilities improve over time.
   

Lyme Disease Testing Market Share

The market is highly competitive, with several key players leading the industry in terms of market share. Many companies dominate the market with a diverse portfolio of diagnostic products, including advanced serological assays like ELISA and Western blot, as well as molecular testing technologies like PCR. Bio-Rad Laboratories, known for its high-precision diagnostics and extensive global reach, holds a significant portion of the market share due to its widespread use of serological tests in clinical settings. bioMérieux, Inc. is another key player, offering both immunoassays and molecular diagnostics, which contribute to its strong market position, especially in North America and Europe.
 

The growth in market share of these companies is primarily driven by factors such as technological advancements in diagnostic tools, the increasing prevalence of Lyme disease, and rising awareness about tick-borne infections. Additionally, strategic partnerships and acquisitions among diagnostic companies enhance their product portfolios and expand their geographic presence, enabling them to capture a larger market share. As the global burden of Lyme disease rises, competition will intensify, with companies continually innovating to meet the needs of clinicians and patients alike.
 

Lyme Disease Testing Market Companies

Prominent players operating in the lyme disease testing industry include:

• bioMérieux
• Bio-Rad Laboratories
• Ceres Nanosciences
• DiaSorin
• Galaxy Diagnostics
• Gold Standard Diagnostics
• IGeneX
• Oxford Immunotec
• T2 Biosystems
• Thermo Fisher Scientific
• Trinity Biotech
• ZEUS Scientific
   

Lyme Disease Testing Industry News:

• On July 2022, T2 Biosystems received approval from the U.S. Food and Drug Administration (USFDA) for the T2Lyme Panel. This diagnostic tool is designed to enhance the accuracy of early Lyme disease detection, potentially improving patient care and outcomes. The T2Lyme Panel directly identifies the Lyme disease-causing bacteria from a patient's blood sample.
• On April 2022, Valneva and Pfizer shared promising results from the Phase 2 trial of their Lyme disease vaccine candidate, VLA15. Based on the positive data, the companies planned to advance with a three-dose primary vaccination schedule and initiate a Phase 3 clinical trial. This trial will evaluate VLA15 in both adults and children aged 5 and above, with plans to begin the trial in 2022, pending regulatory approval.

The lyme disease testing market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Diagnostic Technology

• Serological test
  • ELISA
  • Western blot
• Nucleic acid test
• Urine antigen testing
• Lymphocytic transformation test
• Immunofluorescent staining

Market, By Sample Type

• Blood
• Urine
• CSF
• Other blood samples

Market, By Patient Type

• Adult
• Pediatric

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE